Anti-Cancer Agents in Medicinal Chemistry
Title:Meet Our Editorial Board Member
Volume: 19 Issue: 15
Author(s): L.F. Jave-Suárez
Affiliation:
Export Options
About this article
Cite this article as:
Jave-Suárez L.F. , Meet Our Editorial Board Member, Anti-Cancer Agents in Medicinal Chemistry 2019; 19 (15) . https://dx.doi.org/10.2174/187152061915191212104652
DOI https://dx.doi.org/10.2174/187152061915191212104652 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Never Sleep with Baby? Or Keep Me Close But Keep Me Safe: Eliminating Inappropriate “Safe Infant Sleep” Rhetoric in the United States
Current Pediatric Reviews Preface:
Current Enzyme Inhibition RNA as a Drug Target: Recent Patents on the Catalytic Activity of Trans- Splicing Ribozymes Derived from Group I Intron RNA
Recent Patents on DNA & Gene Sequences Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics A Comprehensive Review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan
Current Cancer Drug Targets DNA Repair in Normal and Cancer Stem Cells, with Special Reference to the Central Nervous System
Current Medicinal Chemistry Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Current Clinical Pharmacology Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets
Current Cancer Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Reversal of Bone Cancer Pain by HSV-1-Mediated Silencing of CNTF in an Afferent Area of the Spinal Cord Associated with AKT-ERK Signal Inhibition
Current Gene Therapy Patent Selections
Recent Patents on Biotechnology Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids
Current Drug Delivery MiR-597 Targeting 14-3-3σ Enhances Cellular Invasion and EMT in Nasopharyngeal Carcinoma Cells
Current Molecular Pharmacology Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Chemotherapy with Gemcitabine in Advanced Biliary Tract Carcinoma
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Targeting Epithelial-to-Mesenchymal Transition for Cancer Therapy)
Current Pharmaceutical Design PDGF/PDGFR Signaling and Targeting in Cancer Growth and Progression: Focus on Tumor Microenvironment and Cancer-associated Fibroblasts
Current Pharmaceutical Design